Sulzer Looking To Double Medical Device Revenues Over Next Two Years
This article was originally published in The Gray Sheet
Executive Summary
Sulzer says it plans to roughly double the size of its core cardiovascular/orthopedic device and materials technology businesses within two years to approximately $2 bil. and at the same time maintain a "significant focus" on biotechnology.
You may also be interested in...
Sulzer Buys Paragon Anticipating Increased Conversion To Dental Implants
Anticipating increased conversion of the tooth replacement market to dental implants from conventional treatments such as bridges and crowns, Sulzer Medica is paying about 3.3 times sales to acquire dental implant maker Core Vent Corporation/Paragon Implant Company. The move roughly doubles Sulzer's share of the $550 mil. dental implant market to about 10.5%.
Sulzer Buys Paragon Anticipating Increased Conversion To Dental Implants
Anticipating increased conversion of the tooth replacement market to dental implants from conventional treatments such as bridges and crowns, Sulzer Medica is paying about 3.3 times sales to acquire dental implant maker Core Vent Corporation/Paragon Implant Company. The move roughly doubles Sulzer's share of the $550 mil. dental implant market to about 10.5%.
Sulzer Medica, Remaining Independent, Contemplates Zimmer Buy
Acquisition of Bristol-Myers Squibb's Zimmer orthopedics business is under consideration by Sulzer Medica, but Sulzer cautions that "the purchase price and other terms of a possible transaction will play an important role in the decision," according to an Oct. 27 announcement.